Literature DB >> 33328303

Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells.

Shun Iida1,2, Sohtaro Mine1, Keiji Ueda3, Tadaki Suzuki1, Hideki Hasegawa1,2, Harutaka Katano4.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is an etiologic agent of Kaposi's sarcoma as well as primary effusion lymphoma (PEL), an aggressive B-cell neoplasm which mostly arises in immunocompromised individuals. Lytic replication of KSHV is also associated with a subset of multicentric Castleman diseases. At present, there is no specific treatment available for PEL and its prognosis is poor. In this study, we found that the histone deacetylase inhibitor suberoyl bis-hydroxamic acid (SBHA) induced KSHV reactivation in PEL cells in a dose-dependent manner. Next-generation sequencing analysis showed that more than 40% of all transcripts expressed in SBHA-treated PEL cells originated from the KSHV genome compared with less than 1% in untreated cells. Chromatin immunoprecipitation assays demonstrated that SBHA induced histone acetylation targeting the promoter region of the KSHV replication and transcription activator gene. However, there was no significant change in methylation status of the promoter region of this gene. In addition to its effect of KSHV reactivation, this study revealed that SBHA induces apoptosis in PEL cells in a dose-dependent manner, inducing acetylation and phosphorylation of p53, cleavage of caspases, and expression of pro-apoptotic factors such as Bim and Bax. These findings suggest that SBHA reactivates KSHV from latency and induces apoptosis through the mitochondrial pathway in PEL cells. Therefore, SBHA can be considered a new tool for induction of KSHV reactivation, and could provide a novel therapeutic strategy against PEL.IMPORTANCE Kaposi's sarcoma and primary effusion lymphoma cells are latently infected with Kaposi's sarcoma-associated herpesvirus (KSHV), whereas KSHV replication is frequently observed in multicentric Castleman disease. Although KSHV replication can be induced by some chemical reagents (e.g. 12-O-tetradecanoylphorbol-13-acetate), the mechanism of KSHV replication is not fully understood. We found that the histone deacetylase inhibitor suberoyl bis-hydroxamic acid (SBHA) induced KSHV reactivation with high efficiency, through histone acetylation in the promoter of the replication and transcription activator gene, compared with 12-O-tetradecanoylphorbol-13-acetate. SBHA also induced apoptosis through the mitochondrial pathway in KSHV-infected cells, with a lower EC50 than measured for viral reactivation. SBHA could be used in a highly efficient replication system for KSHV in vitro, and as a tool to reveal the mechanism of replication and pathogenesis of KSHV. The ability of SBHA to induce apoptosis at lower levels than needed to stimulate KSHV reactivation, indicates its therapeutic potential.
Copyright © 2020 American Society for Microbiology.

Entities:  

Year:  2020        PMID: 33328303      PMCID: PMC8092814          DOI: 10.1128/JVI.01785-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.

Authors:  Emmanuelle Boulanger; Laurence Gérard; Jean Gabarre; Jean-Michel Molina; Christophe Rapp; Jean-François Abino; Jacques Cadranel; Sylvie Chevret; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2005-07-01       Impact factor: 44.544

2.  Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

Authors:  W Gu; R G Roeder
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

3.  High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma.

Authors:  H Katano; Y Sato; T Kurata; S Mori; T Sata
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

4.  Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro.

Authors:  Ke Lan; Tathagata Choudhuri; Masanao Murakami; Daniel A Kuppers; Erle S Robertson
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease.

Authors:  H Katano; Y Sato; T Kurata; S Mori; T Sata
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

6.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

7.  Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.

Authors:  Joel T Adler; Daniel G Hottinger; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

8.  DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

Authors:  S Y Shieh; M Ikeda; Y Taya; C Prives
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

9.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 10.  Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors.

Authors:  Pierre Autin; Christophe Blanquart; Delphine Fradin
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

View more
  2 in total

1.  SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.

Authors:  Wayne W Yeh; Yin-Quan Chen; Wan-Shan Yang; Yung-Chih Hong; Sen Kao; Tze-Tze Liu; Ting-Wen Chen; Lung Chang; Pei-Ching Chang
Journal:  J Virol       Date:  2022-08-01       Impact factor: 6.549

Review 2.  Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.

Authors:  Eleonora Naimo; Jasmin Zischke; Thomas F Schulz
Journal:  Viruses       Date:  2021-09-09       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.